Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). Mazieres, J., Drilon, A. E., Mhanna, L., Milia, J., Lusque, A., Cortot, A. B., Mezquita, L., Thai, A., Couraud, S., Veillon, R., Mascaux, C., Schouten, R., Neal, J. W., Ng, T. L., Frueh, M., Peled, N., Gounant, V., Popat, S., Zhu, V., Gautschi, O. AMER SOC CLINICAL ONCOLOGY. 2018
View details for DOI 10.1200/JCO.2018.36.15_suppl.9010
View details for Web of Science ID 000442916003184